Lyme disease, caused by the bacterium Borrelia burgdorferi and transmitted through tick bites, remains a significant challenge in modern medicine. Its persistent symptoms and the formation of bacterial biofilms make treatment especially difficult in chronic stages. In response to this need, Ion Biotechnology México introduces a revolutionary innovation: Ion Gel ZCM-25®, a topical gel powered by IBAL technology that has demonstrated a 91.341% kill rate of Borrelia burgdorferi within just 10 minutes—without the use of traditional antibiotics.
The study published on ZCM25.com demonstrates how the active ingredient ION-ZCM1, a coordination complex with hexaaqua ligands, combines zinc, copper, magnesium, sulfur, and hydrogen to deliver multiple therapeutic actions:
These properties make Ion Gel ZCM-25® a comprehensive solution, especially beneficial in managing complex conditions like chronic Lyme disease.
Ion Gel ZCM-25® has undergone extensive clinical and preclinical testing with outstanding results:
Approved as a Class II Medical Device by COFEPRIS, Ion Gel ZCM-25® can be seamlessly integrated into treatment protocols across medical institutions in Mexico and Latin America.
In addition to Borrelia burgdorferi, Ion Gel ZCM-25® has proven effective against:
These results reinforce its value as a powerful adjunctive therapy for skin infections, surgical wounds, and inflammatory diseases.
From development to manufacturing, Ion Gel ZCM-25® is a 100% Mexican innovation, backed by clinical research, scientific rigor, and a global support ecosystem through the 2+Cations® Platform, which offers training and tools for healthcare professionals.
Read the full study at here.